Currently, the board of directors are only in Swedish. If you need more information, please contact us.
Chairman of the board
Born 1968. University studies at Chalmers University of Technology and the Gothenburg School of Business.
Board member of Oblique Therapeutics Ab: Member since 2021
Chairman of the Board: Quiq Holding Ab, Postery Ab, Krafthem Ab, Renable Ab, Admazing Ab
Board member: Roscomar Ltd, Workpilots Oy
Shareholding in Oblique Therapeutics Ab: 1,519,330 shares via company
Main work experience: 25 years of experience as CEO of Exertis Nordics Ab, of which the last 7 years in a listed group. History as a serial entrepreneur with several successful exits. Today investor and advisor
Member of the board
Born 1959. Master of Science in Chemical Engineering, Chalmers University of Technology, Gothenburg.
Board member of Oblique Therapeutics Ab: Member since 2021.
Chairman of the Board: MDA Management Ab, Sahlgrenska Science Park Ab, Saminvest Ab, Occlutech Ab and the Royal Swedish Academy of Engineering Sciences (IVA West).
Board member: Linc Ab, Promore Pharma Ab.
Member: Dental and Pharmaceutical Benefits Agency (TLV) transparency council.
Shareholding in Oblique Therapeutics Ab: no shares.
Main work experience: Marianne was previously CEO of Kronans Droghandel Ab, Sjätte AP-fonden and Global Health Partner Ab and Deputy CEO of Apoteket Ab
Member of the board
Born 1951. Master of Science in Engineering, Chalmers University of Technology, Gothenburg.
Board member of Oblique Therapeutics Ab: Member since 2017
Board member: Nordic Tender Ab
Shareholding in Oblique Therapeutics Ab: no shares
Main work experience: Lars has over 25 years of experience in investment banking in the Healthcare sector with a focus on biotechnology and pharmaceuticals. He has previously worked as sector manager in biotechnology and medicine at Industrifonden, sector manager for Healthcare at Alfred Berg / ABN AMRO and as sector manager for Healthcare at Carnegie Investment Bank. Since 2019, Lars has been associated with Carnegie Investment Bank as Senior Adviser within Healthcare. During his years in Investment Banking, he has been an advisor and responsible for a large number of IPOs and new issues as well as public and private M&A in the Nordic capital markets for Calliditas, Cellink, Camurus, Nuevolution, Oncopeptides, Medivir, Wilson Therapeutics, BioArctic, Bonesupport, PledPharma , Alligator Biosciences, Hansa Medical, Recipharm et al
Member of the board
Born 1971. Studied Economics and Law at the School of Business and Economics and at the School of Public Administration, University of Gothenburg.
Board member of Oblique Therapeutics: Chairman of the Board from 2016 -2021 and from 2021 member of the board
Board member: Promore Pharma Ab, S.P. HMSO Göteborg Ab, Inorbit Therapeutics Ab and Deputy Chairman in Alligator Bioscience Ab
Shareholding in Oblique Therapeutics Ab: no shares
Main work experience: Hans-Peter has +20 years of experience in Investment Banking, Private Banking and Asset Management. Hans-Peter has held senior positions at Swedbank Markets, UBS AG, Danske bank and Söderberg & Partners. Hans-Peter has been involved as a board member in Swedish and international companies in Finance and Life Science such as Ancoria Insurance Public Ltd and Irlab Therapeutics Ab
Member of the board
Born 1961. Professor of Molecular Biotechnology, PhD in Biotechnology, Master of Science in Chemical Engineering, Royal Institute of Technology, Stockholm
Board member of Oblique Therapeutics Ab: member since 2021
Chairman of the Board: Royal Institute of Technology Holding Ab, Amylonix Ab
Board member: Intervacc Ab
Member: The Human Protein Atlas Foundation
Shareholding in Oblique Therapeutics Ab: no shares
Main work experience: Professor of molecular biotechnology, dean of KTH biotechnology and founder of several companies in biotechnology, such as Creative Peptides Ab, Affibody Ab, Atlas Therapeutics and Amylonix Ab
Member of the board
Born 1973. Professor of Cellular and Molecular Pain Physiology, Karolinska Institutet, Ph.D in Molecular Pathology, UC San Diego, M.Sc in Pharmaceutical Biosciences, Uppsala University.
Board member of Oblique Therapeutics AB: member since 2021.
Member: Scandinavian Association for the Study of Pain, Stiftelsen Vectis.
Shareholding in Oblique Therapeutics Ab: no shares.
Main work experience: Professor of cellular and molecular pain physiology, research group leader and management team member at the Department of Physiology and Pharmacology, Karolinska Institutet. Member and chairman of the Swedish Young Academy. Scientific advisor and speaker for Cellectricon, Eli Lilly, BMS, Pfizer and others
Member of the board
Born 1968. Professor of Chemical Biology, PhD in Physical Chemistry CTH, Master of Science in Chemical Engineering, Chalmers University of Technology Gothenburg.
Board member of Oblique Therapeutics Ab: member since 2021
Member: Royal Swedish Academy of Sciences (KVA), Royal Swedish Academy of Engineering Sciences (IVA)
Shareholding in Oblique Therapeutics Ab: no shares
Main work experience: Since Ph D 1996, worked 12 years in the USA at the California Institute of Technology, Tulane University, and Rice University, in the last 8 years as a professor at Umeå University and from 2015 professor at Chalmers. Scientific expertise and experimental research on the biophysics of proteins with a focus today on proteins in cancer and neurodegeneration. Published over 250 scientific articles. A number of international and national assignments over the years, such as the Biophysical Society's board, KAW, VR (NT Council 2010-2012). Leads Genie, a major gender equality initiative, at Chalmers since 2019. Member of KVA, IVA and the Nobel Prize Committee for Chemistry. Advisor to the Nobel Museum and scientific advisor Axial Therapeutics
